Therapy Areas: Hereditary Disorders
AmpliPhi Biosciences Preclinical Data Shows AB-PA01 Reduces Biofilms of Pseudomonas Aeruginosa
3 October 2017 - - San Diego, California-based developer of therapies for antibiotic-resistant infections using bacteriophage-based technology AmpliPhi Biosciences Corp. (NYSE MKT: APHB) has published preclinical data demonstrating the activity of AB-PA01 in reducing biofilms, the company said.
The paper, titled "Activity of Bacteriophages in Removing Biofilms of Pseudomonas aeruginosa Isolates from Chronic Rhinosinusitis Patients," was published on September 22, 2017, in the journal Frontiers in Cellular and Infection Microbiology.
The research assessed the activity of AB-PA01, AmpliPhi's drug candidate that contains four specific bacteriophages (referred to as CT-PA), in eradicating biofilms of ex vivo P. aeruginosa isolates from chronic rhinosinusitis patients (CRS). P. aeruginosa isolates from CRS patients with and without cystic fibrosis collected across three continents were multi-locus sequence typed and tested for antibiotic resistance.
Biofilms grown in vitro were treated with AB-PA01 and biofilm biomass was measured after 24 and 48 hours, using a crystal violet assay.
The isolates included 44 strain types. Bacteriophage treatment significantly reduced biofilm biomass at both 24 and 48 hours post-treatment (p < 0.0001), regardless of CF status or antibiotic resistance profiles.
Bacteriophages, or more simply "phages," are the natural predators of bacteria and are thought to be the most abundant life form on earth.
Phages have evolved an incredible diversity of strains that typically prey upon just a few closely related strains or species of bacteria, enabling phage therapies to precisely target pathogenic bacteria while sparing the beneficial microbiota. Phages can infect and kill bacteria, whether they are antibiotic-resistant or not, and even when they have formed protective biofilms.
AmpliPhi Biosciences is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology.
Its lead product candidates target multidrug-resistant S. aureus and P. aeruginosa, which are included on the WHO's 2017 Priority Pathogens List.
Login
Username:

Password:


Related Headlines

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy

Markels Named to Arcturus Therapeutics Board of Directors

SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis

Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638

Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera